Browsing by Subject "drug"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Bioinformatics and Pharmacogenomics in Drug Discovery and Development
    Anyanwu, Chukwuma Eustace; Jones, Josette
    Objective: Literature review to evaluate the extent to which Bioinformatics has facilitated the drug discovery and development process from an economic perspective Problem: A plethora of genomic and proteomic information was uncovered by the U.S Human Genome Project (HGP). Despite the projected impact that Bioinformatics and Pharmacogenomics were projected to have in the drug discovery and development process, the challenges facing the pharmaceutical companies – in this regard, still persist. Design: An extensive integrated literature review of library resources such as MEDLINE, ERIC, PsychInfo, EconLit, Social Services Abstracts, ABI/INFORM and LISA (all 1990 – Present). These electronic databases were researched because of their focuses on the healthcare sector, medical and scientific innovations, economic modeling and analysis, bioinformatics and computational biology, applied social research and technology applications. Semi-structured interviews of Bioinformatics professionals were also conducted to complement the literature review. Also, Internet-based databases from reliable resources were also researched resulting in serendipitous discoveries. Sample: Published English language reports of studies and research carried out worldwide from 1990 to 2004, relating to drug discovery and development. Selection criteria: Primary focus was on research publications and journals that identify and discuss the practice of Bioinformatics, especially in the area of drug discovery and development. Premium was placed on articles and publications that discussed the economic impacts of Bioinformatics in the drug discovery process. Results: Though the goals of Bioinformatics have been clearly defined, and the discipline is widely practiced in the pharmaceutical industry, this study has not found any definite attempts to evaluate its economic and regulatory impact specifically in facilitating the drug discovery and development process, and the delivery of personalized drugs. Discussion: Bioinformatics and Pharmacogenomics are the new facets of the ever-evolving drug discovery and development process. It may still be a while before their full impact and potential is attained.
  • Thumbnail Image
    Item
    Daily Situational Brief, June 20, 2011
    (MESH Coalition, 6/20/2011) MESH Coalition
  • Thumbnail Image
    Item
    Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs
    (Frontiers, 2020-06-12) Angel, Sergio O.; Vanagas, Laura; Ruiz, Diego M.; Cristaldi, Constanza; Saldarriaga Cartagena, Ana M.; Sullivan, William J., Jr.; Pharmacology and Toxicology, School of Medicine
    Toxoplasma gondii is the causative agent of toxoplasmosis in animals and humans. This infection is transmitted to humans through oocysts released in the feces of the felines into the environment or by ingestion of undercooked meat. This implies that toxoplasmosis is a zoonotic disease and T. gondii is a foodborne pathogen. In addition, chronic toxoplasmosis in goats and sheep is the cause of recurrent abortions with economic losses in the sector. It is also a health problem in pets such as cats and dogs. Although there are therapies against this infection in its acute stage, they are not able to permanently eliminate the parasite and sometimes they are not well tolerated. To develop better, safer drugs, we need to elucidate key aspects of the biology of T. gondii. In this review, we will discuss the importance of the homologous recombination repair (HRR) pathway in the parasite's lytic cycle and how components of these processes can be potential molecular targets for new drug development programs. In that sense, the effect of different DNA damage agents or HHR inhibitors on the growth and replication of T. gondii will be described. Multitarget drugs that were either associated with other targets or were part of general screenings are included in the list, providing a thorough revision of the drugs that can be tested in other scenarios.
  • Thumbnail Image
    Item
    Worldwide Variations in Demographics, Management, and Outcomes of Acute Pancreatitis
    (Elsevier, 2019) Matta, Bassem; Gougol, Amir; Gao, Xiaotian; Reddy, Nageshwar; Talukdar, Rupiyoti; Kochhar, Rakesh; Goenka, Mahesh Kumar; Gulla, Aiste; Gonzalez, Jose A.; Singh, Vikesh K.; Ferreira, Miguel; Stevens, Tyler; Barbu, Sorin T.; Nawaz, Haq; Gutierrez, Silvia C.; Zarnescu, Narcis O.; Capurso, Gabriele; Easler, Jeffrey; Triantafyllou, Konstantinos; Pelaez-Luna, Mario; Thakkar, Shyam; Ocampo, Carlos; de-Madaria, Enrique; Cote, Gregory A.; Wu, Bechien U.; Paragomi, Pedram; Pothoulakis, Ioannis; Tang, Gong; Papachristou, Georgios I.; Medicine, School of Medicine
    Background & Aims Few studies have compared regional differences in acute pancreatitis. We analyzed data from an international registry of patients with acute pancreatitis to evaluate geographic variations in patient characteristics, management, and outcomes. Methods We collected data from the APPRENTICE registry of patients with acute pancreatitis, which obtains information from patients in Europe (6 centers), India (3 centers), Latin America (5 centers), and North America (8 centers) using standardized questionnaires. Our final analysis included 1,612 patients with acute pancreatitis (median age, 49 years; 53% male, 62% white) enrolled from August 2015 through January 2018. Results Biliary (45%) and alcoholic acute pancreatitis (21%) were the most common etiologies. Based on the revised Atlanta classification, 65% of patients developed mild disease, 23% moderate, and 12% severe. The mean age of patients in Europe (58 years) was older than mean age for all 4 regions (46 years) and a higher proportion of patients in Europe had comorbid conditions (73% vs 50% overall). The predominant etiology of acute pancreatitis in Latin America was biliary (78%), whereas alcohol-associated pancreatitis accounted for the highest proportion of acute pancreatitis cases in India (45%). Pain was managed with opioid analgesics in 93% of patients in North America versus 27% of patients in the other 3 regions. Cholecystectomies were performed at the time of hospital admission for most patients in Latin America (60% vs 15% overall). A higher proportion of European patients with severe acute pancreatitis died during the original hospital stay (44%) compared with the other 3 regions (15%). Conclusions We found significant variation in demographics, etiologies, management practices, and outcomes of acute pancreatitis worldwide.